PDCD1 and non-small cell lung carcinoma: Thereafter, also anti PD-1/PD-L1 mAbs were tested against tumors that were classically considered to be poorly immunogenic and mostly unresponsive to immunotherapy, such as non-small cell lung cancer (NSCLC); however, these drugs demonstrated impressive and long-lasting anticancer activity in a minority of patients [21,22,23,24,25].